Barclays PLC vs Summit Therapeutics Inc — how do they compare? Barclays PLC trades at $28.04 (market cap $93.87B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Barclays PLC is far larger — about 7.8× Summit Therapeutics Inc's market cap, and Barclays PLC pays a 2.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BCS | SMMT | |
|---|---|---|
Market Cap | $93.87B | $12.06B |
Sector | Financials | Health |
52-Week High | $28.56 | $26.98 |
52-Week Low | $19.36 | $12.55 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $11.39B |
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.09, up 0.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a low P/E of 10.68 and P/B of 0.88, indicating potential undervaluation. Revenue grew to $29.14B in 2025, with net income margin at 25.51%, though cash flow volatility from 2023-2024 remains a concern. Recent news highlights a securities investigation and mixed analyst views post-Q2 results.
Outlook is cautiously optimistic due to valuation appeal and earnings strength, but risks include legal scrutiny and cost pressures. Analyst consensus is 68% buy, with sentiment tempered by near-term headwinds. The stock offers value if operational efficiency improves, yet investors should monitor the class-action probe and expense trends.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Trailing returns across standard periods
Latest headlines on both assets
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →